Monkey pox: the European Medicines Agency approves the use of the Imvanex vaccine against Monkeypox

The EMA gave the green light on July 22 to “extend the indication of the smallpox vaccine Imvanex” to adults against monkeypox.

L’European Medicines Agencyts (EMA) approved this Friday the Imvanex vaccine in the European Union against monkeypox in adults. This serum is initially destined to fight against human smallpox.

Already authorized in France, Imvanex is manufactured by the Danish company Bavarian Nordic.

It has been approved against monkeypox due to the similarity between this virus and the smallpox virus. First detected in humans in 1970, monkeypox is less dangerous and contagious than its cousin smallpox, eradicated in 1980.

Read also :
Monkey pox: a confirmed case in Spain in a 7-month-old baby whose parents had been infected

More than 15,300 cases

This Thursday, the WHO expressed its concern about the increase in the number of cases and sought the advice of experts, before possibly declaring the “public health emergency of international concern”, the most high level of organizational alertness.

Read also :
Monkey pox: “It won’t take long to declare a pandemic”, warns a WHO expert

Over 15,300 cases of monkeypox have been reported in 71 countries around the world.

Read also :
Monkey pox: 14,000 cases of contamination and five confirmed deaths worldwide, new WHO emergency meeting this Thursday

Leave a Comment